# A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

> clinical trial · VERIFIED · 2026-07-22

Status: RECRUITING · Sponsor: Hoffmann-La Roche · Condition: Neovascular Age-related Macular Degeneration

- Company: Hoffmann-La Roche
- Sector: Neovascular Age-related Macular Degeneration
- Primary source: https://clinicaltrials.gov/study/NCT06847542

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.